AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
April 12 2022 - 8:00AM
Business Wire
New clamp is designed to improve efficiency of
concomitant ablation procedures
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments and therapies for atrial fibrillation (Afib), left
atrial appendage (LAA) management and post-operative pain
management, today announced that it has launched the EnCompass
Clamp®, a part of the Isolator Synergy™ Ablation System in the
United States. The EnCompass Clamp received FDA 510(k) clearance
for ablation of cardiac tissue during cardiac surgery and is
designed to make concomitant surgical ablations more efficient.
The EnCompass Clamp includes features such as parallel closure,
uniform pressure, and custom power using Synergy radiofrequency
(RF). The new features of the EnCompass Clamp allow for easier
placement using a magnetic guide, which enables more efficient
procedures by minimizing tissue dissection.
“The EnCompass Clamp provides a simpler and faster approach to
ablating the heart in open-chest procedures,” said Michael Carrel,
President and Chief Executive Officer of AtriCure. “We are
passionate about innovation, leading to high-quality options for
our physician partners. We believe the EnCompass Clamp will meet
the unique needs of surgeons who are performing closed-atrium
cardiac surgery.”
“This new device has become an invaluable part of the way I
perform surgical ablation,” said Dr. Prem Samuel, a cardiothoracic
surgeon at Midwest Heart & Vascular Specialists, Kansas City,
Missouri. “It is used with minimal dissection and creates lesions
around the pulmonary veins and the entire posterior wall of the
left atrium without opening the atrium, all in a single pass
through the transverse and oblique sinuses. I’ve seen firsthand the
gains in efficiency that the EnCompass Clamp can bring to my
practice and patients.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first medical
device to receive FDA approval for the treatment of persistent
Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System
products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure
that provides a lasting solution for long-standing persistent Afib
patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for
temporary ablation of peripheral nerves to block pain, providing
pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220412005024/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com Valerie Storch-Willhaus AtriCure,
Inc. Vice President, Corporate Marketing and Communications (612)
424-8359 vstorch-willhaus@atricure.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024